These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17112844)

  • 1. Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen.
    Kahan BD; Podbielski J; Schoenberg L
    Transplant Proc; 2006 Nov; 38(9):2842-6. PubMed ID: 17112844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-a-day administration of everolimus, cyclosporine, and steroid after renal transplantation: a review of the rationale.
    Corbetta G; Ponticelli C
    Transplant Proc; 2010 May; 42(4):1303-7. PubMed ID: 20534286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid.
    Citterio F; Sparacino V; Altieri P; Rigotti P; Calabrese S; Poli M; Vinti V; Segoloni GP
    Transplant Proc; 2005 Mar; 37(2):827-9. PubMed ID: 15848545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R; Segoloni G; Campistol JM; Kreis H; Mota A; Lawen J; Russ G; Grinyó JM; Stallone G; Hartmann A; Pinto JR; Chapman J; Burke JT; Brault Y; Neylan JF;
    Transpl Int; 2005 Jan; 18(1):22-8. PubMed ID: 15612979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
    Knight RJ; Kerman RH; McKissick E; Lawless A; Podder H; Katz S; Van Buren CT; Kahan BD
    Clin Transplant; 2008; 22(5):645-50. PubMed ID: 18657156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W; Schoenberg L; Lasky RE; Kahan BD
    Transplant Proc; 2007 Dec; 39(10):3086-92. PubMed ID: 18089328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants.
    Petero VG; Kaposztas Z; Kahan BD
    Clin Transplant; 2010; 24(2):243-51. PubMed ID: 19694771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
    Saudi J Kidney Dis Transpl; 2008 Jul; 19(4):564-70. PubMed ID: 18580014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients.
    Langer RM; Kahan BD
    Transplantation; 2003 Jul; 76(2):318-23. PubMed ID: 12883185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
    Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
    Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD
    Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
    Russ G; Jamieson N; Oberbauer R; Arias M; Murgia MG; Blancho G; Sato R; Stoeckl M; Revicki DA
    Transpl Int; 2007 Oct; 20(10):875-83. PubMed ID: 17854445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
    Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
    Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cessation of steroids in stable renal transplant patients: the Leuven experience.
    Maes BD; Claes K; Coosemans W; Evenpoel P; Kuypers D; Pirenne J; Vanrenterghem Y
    Clin Transpl; 2002; ():181-9. PubMed ID: 12971448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.